Wednesday, July 01, 2015 1:25:01 PM
Excerpt from most recent 10Q
In February 2015, the Company purchased an exclusive license to an intravenous (“IV”) formulation of Tramadol for the U.S. market from Revogenex Ireland Ltd (“Revogenex”), a privately held company in Dublin, Ireland. Fortress made an upfront payment of $2.0 million to Revogenex upon execution of the exclusive license included in research and development licenses-acquired on the Condensed Consolidated Statement of Operations, with an additional $1.0 million due 120 days later and after receiving all the assets acquired in this agreement. Under the terms of the agreement Revogenex is eligible to receive additional milestone payments upon the achievement of certain development milestones, in addition to royalty payments for sales of the product. Tramadol is a centrally acting synthetic opioid analgesic for moderate to moderately severe pain and is available as immediate release or extended-release tablets in the United States. In connection with this purchase, the Company formed a Fortress subsidiary, Avenue, to acquire, in-license, develop and commercialize products principally for use in the U.S. hospital market. The Company will transfer the Revogenex license to Avenue during the first half of 2015.
Regards
Sunny:>)))
Recent FBIO News
- Mustang Bio Announces Closing of $4 Million Public Offering • GlobeNewswire Inc. • 05/02/2024 08:01:07 PM
- Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer • GlobeNewswire Inc. • 05/01/2024 08:01:30 PM
- Mustang Bio Announces Pricing of $4 Million Public Offering • GlobeNewswire Inc. • 04/30/2024 12:00:07 AM
- Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds • GlobeNewswire Inc. • 04/29/2024 12:00:14 PM
- Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 • GlobeNewswire Inc. • 04/25/2024 12:30:48 PM
- Avenue Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 04/24/2024 11:30:41 AM
- Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/28/2024 08:05:13 PM
- Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases • GlobeNewswire Inc. • 03/28/2024 01:00:51 PM
- Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 • GlobeNewswire Inc. • 03/25/2024 12:30:00 PM
- Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/21/2024 08:01:27 PM
- Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/18/2024 08:05:14 PM
- Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea • GlobeNewswire Inc. • 03/18/2024 12:30:30 PM
- Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 • GlobeNewswire Inc. • 03/15/2024 12:30:01 PM
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq • GlobeNewswire Inc. • 03/15/2024 12:15:01 PM
- Journey Medical Corporation to Participate in the 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/13/2024 12:30:14 PM
- Fortress Biotech to Participate in 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/12/2024 12:30:16 PM
- Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting • GlobeNewswire Inc. • 03/11/2024 12:30:30 PM
- Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting • GlobeNewswire Inc. • 03/11/2024 12:00:17 PM
- Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma • GlobeNewswire Inc. • 03/07/2024 12:30:12 PM
- Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease • GlobeNewswire Inc. • 03/04/2024 01:30:24 PM
- Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy • GlobeNewswire Inc. • 02/22/2024 01:30:08 PM
- Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference • GlobeNewswire Inc. • 01/11/2024 01:30:39 PM
- Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference • GlobeNewswire Inc. • 01/11/2024 01:00:08 PM
- Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds • GlobeNewswire Inc. • 01/05/2024 02:15:43 PM
- Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea • GlobeNewswire Inc. • 01/05/2024 01:30:12 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM